Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "genentech"

Researchers at Genentech, Inc. Have Reported New Data on Immun...

Researchers at Genentech, Inc. Have Reported New Data on Immunoglobulins (Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies) By a News Reporter-Staff News Editor at Drug Week -- Investigators publish ... 4 Traders, 17 hours ago

Genentech Partnering Deals and Alliances 2010 to 2016 - New Market Report

Fast Market Research announces the availability of the new Current Partnering report, "Genentech Partnering Deals and Alliances 2010 to 2016", on their comprehensive research portal This press release was orginally distributed by SBWire ...
 Digital Journal1 week ago Global Endocrinology Drugs Market to Set at CAGR of 6.69% Between 2016-2020: MarketResearchReports.biz  Digital Journal23 hours ago Endocrinology Drugs Market Global Research and Analysis Report 2016 - 2020  Before It's News1 day ago Endocrinology Drugs Global Market 2016 to 2020  Before It's News3 days ago
[x]  

Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study

Funding This study was designed and funded by Genentech, Inc., South San Francisco, Calif, and Novartis Pharma AG, Basel, Switzerland. D. T. Umetsu, G. J. Carrigan, and A. Rahmaoui are employees of Genentech, Inc. and participated in data ...
 Journal of Allergy and Clinical Immunology2 days ago

Researchers from Genentech, Inc. Detail Findings in Gliomas (Determining priority signs and symptoms for use as clinical outcomes assessments in...

 4 Traders1 week ago

Astex and Genentech to evaluate guadecitabine with atezolizumab to treat AML

Astex Pharmaceuticals has entered a clinical collaboration with Genentech to evaluate the potential of combining guadecitabine (SGI-110) with atezolizumab in the treatment of acute myeloid leukaemia (AML). Guadecitabine is Astex's next-generation ...
 Drug Development Technology1 week ago Astex, Genentech partner to explore combination treatment for acute myeloid leukemia  Pharmaceutical Business Review1 week ago Astex Pharmaceuticals Enters Clinical Trial Collaboration with Genentech  American Pharmaceutical Review1 week ago OTSUKA : U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia  4 Traders1 week ago
[x]  

Astex Pharma and Genentech Forge a Clinical Trial Deal for Acute Myeloid Leukemia

By Alex Keown , BioSpace.com Breaking News Staff PLEASANTON, Calif. -- Astex Pharmaceuticals, Inc. ( ASTX ), a subsidiary of Japan-based Otsuka Pharmaceutical Co. Ltd. , forged a deal with Genentech ( RHHBY ) to develop a combination treatment for ...
 BioSpace1 week ago

Stand Up to Cancer Debuts Catalyst Research Program With Merck, BMS and Genentech

Stand Up To Cancer announced Catalyst, a program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment. Founding ...
 Cancer Letter.com1 week ago
Minyanville

FDA Approves Second Biosimilar, Despite Concerns

The U.S. Food and Drug Administration (FDA) approved the second biosimilar since issuing its draft labeling guidelines for these novel, complex drugs in late March—despite ongoing concerns about patent protection and patient safety. 1 This ...
 Cancer Therapy Advisor14 hours ago Boston Properties, Inc. (NYSE:BXP) CEO Owen Thomas on Q1 2016 Results - Earnings Call Transcript  Seeking Alpha1 day ago FDA Approves Cabometyx  CPhI.cn2 days ago NewLink Genetics Reports First Quarter 2016 Financial Results  PM 3601 hour ago
[x]  

Strange Gilead Should Start By Buying Medivation

Gilead is strange Gilead (NASDAQ: GILD ) has returned a staggering $21 billion in share buybacks ($18 billion) and dividends ($3 billion) since the beginning of 2015. While this is something that would be considered very impressive in any other ...
 Seeking Alpha1 hour ago

ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

− Conference call at 8:00 am ET today will include update on mirvetuximab soravtansine, the first folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), including the design of the FORWARD I trial − WALTHAM, Mass.--(BUSINESS ...
 CNBC3 hours ago IMMUNOGEN : Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update  4 Traders3 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - genentech
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less